Among all breast cancer patients, 88 were hormone receptor positive (HR +) patients (39 Luminal A patients and 49 Luminal B patients), 17 were human epidermal receptor positive (Her-2 +) patients and 28 were triple negative breast cancer (TNBC) patients. This evidence concerns the gene ERBB2 and breast carcinoma.